Inclusion Criteria:

   - Confirmation of cancer by biopsy (tissue sample)

   - Phase 1: patients with advanced or metastatic disease that have failed conventional
   therapy

   - Phase 2: patients with previously untreated NSCLC, excluding squamous cell histology
   and cavitating lesions

   - Age ≥18 years

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-1

   - Adequate renal, liver and bone marrow function.

   - Negative pregnancy test (serum or urine) in females of childbearing potential within 7
   days of the initial dose of aflibercept

   - Ability to comply with scheduled visits, treatment plans, laboratory tests, and other
   study procedures

   - Institutional Review Board (IRB) approved, signed and dated informed consent form

Exclusion Criteria:

   - Prior treatment with study medications

   - Untreated, symptomatic, or progressive Central Nervous System cancer and/or spinal
   cord compression. Patients with treated brain metastases must have been without
   symptoms for at least 3 months

   - Surgery up to 4 weeks prior to the initial administration of aflibercept and/or
   incomplete wound healing

   - Anti-VEGF therapy up to 4 weeks prior to the initial administration of aflibercept
   (for phase 1 only)

   - Chemotherapy up to 4 weeks prior to the initial administration of aflibercept (for
   phase 1 only)

   - Other investigational treatment up to 4 weeks prior to the initial administration of
   aflibercept

   - Any of the following up to 6 months (24 weeks) prior to the initial administration of
   aflibercept:

      - Severe cardiovascular disease or event

      - Cerebrovascular accident, transient ischemic attack, or moderate to severe
      peripheral neuropathy

      - Erosive esophagitis or gastritis, infectious or inflammatory bowel disease, and
      diverticulitis

      - Deep vein thrombosis, pulmonary embolism, or other clotting event

      - Episode(s)of moderate to severe, continuous bleeding

   - Breast-feeding or pregnancy